Seneca Biopharma, Inc. (SNCA): Price and Financial Metrics

Seneca Biopharma, Inc. (SNCA): $9.96

-0.12 (-1.19%)

POWR Rating

Component Grades













Add SNCA to Watchlist
Sign Up

Industry: Biotech



in industry

SNCA Stock Price Chart Interactive Chart >

Price chart for SNCA

SNCA Price/Volume Stats

Current price $9.96 52-week high $10.03
Prev. close $1.68 52-week low $0.50
Day low $9.72 Volume 194,116
Day high $10.03 Avg. volume 3,775,260
50-day MA $1.58 Dividend yield N/A
200-day MA $1.02 Market Cap 172.27M

Seneca Biopharma, Inc. (SNCA) Company Bio

Seneca Biopharma, Inc. operates as a biopharmaceutical company. The Company develops novel treatments for diseases of unmet medical need. Seneca Biopharma serves customers in the State of Maryland.

SNCA Latest News Stream

Event/Time News Detail
Loading, please wait...

SNCA Latest Social Stream

Loading social stream, please wait...

View Full SNCA Social Stream

Latest SNCA News From Around the Web

Below are the latest news stories about Seneca Biopharma Inc that investors may wish to consider to help them evaluate SNCA as an investment opportunity.

Seneca Biopharma Announces Successful Approval of Merger with Leading Biosciences, Inc.

Seneca Biopharma, Inc. (Nasdaq: SNCA) ("Seneca" or the "Company"), disclosed on April 23, 2021, the passing of the final proposal required for approval of the proposed merger between Seneca and Leading Biosciences, Inc. ("LBS"). The Merger is expected to close on or about April 27, 2021 and the new combined company, Palisades Bio, is expected to begin trading on the Nasdaq Capital Market on or about April 28, 2021 under the ticker "PALI".

Yahoo | April 26, 2021

Today’s Biggest Pre-Market Movers: 10 Top Gainers and Losers on Thursday Morning

Thursday's here and we're taking a look at the biggest pre-market movers investors will want to know about before the opening bell.

William White on InvestorPlace | April 22, 2021

Leading BioSciences Announces Early Efficacy Signal in Reducing Post-Surgical Adhesions in Open Label Study

CARLSBAD, Calif., April 20, 2021 (GLOBE NEWSWIRE) -- Leading BioSciences, Inc. (“LBS” or "the Company"), a privately held company that recently entered into a definitive agreement for a reverse merger with Seneca Biopharma, Inc. (Nasdaq: SNCA), subject to certain conditions to be completed, to form Palisade Bio, Inc., announced data from an open label GI surgery study with lead asset LB1148 that provided an early indication of efficacy signal in reducing post-surgical adhesions following elective bowel resection. No abdominal adhesions were observed at the time of a follow-up surgery in two patients treated with LB1148. Although these are early data in a limited number of patients, the data may support the Company's ongoing Phase 2 clinical trial to evaluate the impact of LB1148 on retu...

Yahoo | April 20, 2021

Leading BioSciences Releases Video Message Encouraging Seneca Biopharma, Inc. Stockholders to Vote at the Virtual Special Meeting on April 23, 2021

Video messages urges Seneca stockholders to vote in support of Proposal #1, the reverse stock split, in order to approve the proposed transaction. Proposal 1 was favored by a wide margin by Seneca stockholders who voted at the virtual Special Meeting on April 9, 2021. CARLSBAD, Calif., April 12, 2021 (GLOBE NEWSWIRE) -- Leading BioSciences, Inc. (“LBS”), a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal complications, today released a video message from its CEO, Dr. Tom Hallam, to address the status of the proposed merger transaction with Seneca Biopharma, Inc. (Nasdaq: SNCA) (“Seneca”). All proposals, with the exception of Proposal #1, the reverse stock split (the “Reverse Split Proposal”), have been approved by Seneca stockholders. The Reverse S...

Yahoo | April 13, 2021

Seneca Biopharma, Inc. Announces (i) Voting Results from the Special Meeting of Stockholders and (ii) New Special Meeting Date of April 23, 2021

Seneca Biopharma, Inc. (Nasdaq: SNCA) ("Seneca" or the "Company"), announced the preliminary voting results of its Special Meeting of Stockholders on April 9, 2021. At the Special Meeting, Seneca asked stockholders to approve six proposals related to its proposed merger transaction with Leading BioSciences, Inc. ("LBS"), a biopharma company advancing therapies for acute and chronic gastrointestinal complications. All proposals, with the exception of proposal #1 for a reverse stock split (the "Reverse Split Proposal"), were approved by Seneca stockholders. In order to solicit additional votes for the Reverse Split Proposal, the Special Meeting was adjourned only with respect to the Reverse Split Proposal until April 23, 2021 at 11:00 AM ET and will be held virtually at www.virtualshareho...

Yahoo | April 12, 2021

Read More 'SNCA' Stories Here

SNCA Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year 40.68%
5-year -95.68%
2022 N/A
2021 0.00%
2020 -11.11%
2019 -84.03%
2018 -81.98%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6406 seconds.